Mice overexpressing progastrin are predisposed for developing aberrant colonic crypt loci in response to AOM

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 278, Issue 3 41-3, 2000, Pages

  Singh, Pomila ^a   Velasco, Marco ^b   Given, Randall ^a   Wargovich, Michael ^b   Varro, Andrea ^c   Wang, Timothy C ^d  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Transgenic mice

Indexed keywords

AZOXYMETHANE; BROXURIDINE; GASTRIN; PROGASTRIN; RECEPTOR SUBTYPE;

ARTICLE; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; COLON CARCINOGENESIS; COLON CARCINOMA; CONTROLLED STUDY; CRYPT CELL; FEMALE; GENE OVEREXPRESSION; MALE; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034019304     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.2000.278.3.g390     Document Type: Article

References (52)

1. American Cancer Society. Cancer Facts and Figures-1999. Atlanta, GA: American Cancer Society, 1999, p. 1-36.
2. Baldwin, G. S., and A. Shulkes. Gastrin, gastrin receptors and colorectal carcinoma. Gut 42: 581-584, 1998.
3. Brattain, M. G., G. Howell, L. Z. Sun, and J. K. Willson. Growth factor balance and tumor progression. Curr. Opin. Oncol. 6: 77-81, 1994.
4. Ciccotosto, G. D., A. McLeish, K. J. Hardy, and A. Shulkes. Expression, processing, and secretion of gastrin in patients with colorectal carcinoma. Gastroenterology 109: 1142-1153, 1995.
5. Czerwinski, G., N. I. Tarasova, and C. J. Michejda. Cytotoxic agents directed to peptide hormone receptors-defining the requirements for a successful drug. Proc. Natl. Acad. Sci. USA 95: 11520-11525, 1998.
6. Dai, B., Z. Xu, B. Dhruva, R. Espejo, and P. Singh. Gastrin gene expression in human colon cancer cells: autocrine role of gastrin (Abstract). Gastroenterology 102: A352, 1992.
7. Detjen, K., M. C. Fenrich, and C. D. Logsdon. Transfected CCK receptors mediate growth inhibitory effects on human pancreatic cancer cell lines. Gastroenterology 112: 952-959, 1997.
8. Hollande, F., A. Imdahl, T. Mantamadiotis, G. Ciccotosto, D. Shulkes, and G. S. Baldwin. Glycine-extended gastrin acts as an autocrine growth factor in a nontransformed colon cell line. Gastroenterology 113: 1576-1588, 1997.
9. Imdahl, A., T. Mantamadiotis, S. Eggstein, E. H. Farthmann, and G. S. Baldwin. Expression of gastrin, gastrin/CCK-B and gastrin/CCK-C receptors in human colorectal carcinomas. J. Cancer Res. Clin. Oncol. 121: 661-666, 1995.
10. Iwase, K., B. M. Evers, M. R. Hellmich, Y. S. Guo, S. Higashide, H. J. Kim, and C. M. Townsend, Jr. Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin. Gastroenterology 113: 782-790, 1997.
11. Jen, J., S. M. Powell, N. Papadopoulos, K. J. Smith, S. R. Hamilton, B. Vogelstein, and K. W. Kinzler. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 54: 5523-5526, 1994.
12. Kennedy, E. P., and S. R. Hamilton. Genetics of colorectal cancer. Semin. Surg. Oncol. 15: 126-130, 1998.
13. Kinzler, K. W., and B. Vogelstein. Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996.
14. Langhans, N., G. Rindi, M. Chiu, J. F. Rehfeld, B. Ardman, M. Beinborn, and A. S. Kopin. Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology 112: 280-286, 1997.
15. Lawley, P. D. Carcinogenesis by alkylating agents. In: Chemical Carcinogens, edited by C. D. Searle. Washington, DC: American Chemical Society, 1984, p. 325-484 (ACS Monograph 182).
16. Lipkin, M. Biomarkers of increased susceptibility to gastrointestinal cancer: new application to studies of cancer prevention in human subjects. Cancer Res. 48: 235-245, 1988.
17. Maltzman, T., J. Whittington, L. Driggers, J. Stephens, and D. Ahnen. AOM-induced mouse colon tumors do not express full-length APC protein. Carcinogenesis 18: 2435-2439, 1997.
18. McLellan, A., and R. P. Bird. Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res. 48: 6187-6192, 1988.
19. McLellan, E. A., and R. P. Bird. Specificity study to evaluate induction of aberrant crypts in murine colons. Cancer Res. 48: 6182-6186, 1988.
20. McWilliams, D. F., S. A. Watson, D. M. Crosbee, D. Michaeli, and R. Seth. Coexpression of gastrin and gastrin receptors (CCK-B and delta CCK-B) in gastrointestinal tumor cell lines. Gut 42: 795-798, 1998.
21. Mihas, A. A., R. J. Maliakkal, M. Shueke, and J. L. Achord. Serum gastrin levels in patients with colorectal cancer and adenomatous polyps - a prospective study. Res. Commun. Mol. Pathol. Pharmacol. 90: 301-304, 1995.
22. Moen, C. J., M. A. van der Valk, R. P. Bird, A. A. Hart, and P. Demanded. Different genetic susceptibility to aberrant crypts and colon adenomas in mice. Cancer Res. 56: 2382-2386, 1997.
23. Nakata, H., S. Wang, D. C. Chung, J. K. Westwick, and L. G. Tillotson. Oncogenic ras induces gastrin gene expression in colon cancer. Gastroenterology 115: 1144-1153, 1998.
24. Nemeth, J., B. Taylor, S. Pauwels, A. Varro, and G. J. Dockray. Identification of progastrin derived peptides in colorectal carcinoma extracts. Gut 34: 90-95, 1993.
25. Niv, Y., M. Heizelracht, S. A. Lamprecht, A. D. Sperber, G. M. Fraser, and B. Schwartz. Gastrin levels in colorectal cancer. Isr. J. Med. Sci. 33: 186-189, 1997.
26. Olivo, S., and M. J. Wargovich. Inhibition of aberrant crypt foci by chemo preventive agents. In Vivo 12: 159-166, 1998.
27. Orbuch, M., D. J. Venzon, I. A. Lubensky, H. C. Weber, F. Gibril, and R. T. Jensen. Prolonged hypergastrinemia does not increase the frequency of colonie neoplasia in patients with Zollinger-Ellison syndrome. Dig. Dis. Sci. 41: 604-613, 1996.
28. Penman, I. D., E. El-Omar, J. E. S. Ardill, J. R. McGregor, D. J. Galloway, and P. J. O'Dwyer. Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumor resection. Gastroenterology 100: 1264-1270, 1994.
29. Pinson, D. M., N. Havu, M. I. Sztern, H. Mattsson, G. A. Looney, B. F. Kimler, and A. Hurwitz. Drug-induced hypergastrinemia: absence of trophic effects on colonie carcinoma in rats. Gastroenterology 108: 1068-1074, 1995.
30. Pretlow, T. P., B. J. Barrow, W. S. Ashton, M. A. O'Riodan, T. G. Pretlow, J. A. Jurcisek, and T. A. Stellato. Aberrant crypts: putative preneoplastic foci in human colon mucosa. Cancer Res. 51: 1564-1567, 1991.
31. Reddy, B. S. Nutritional factors and colon cancer. Crit. Rev. Food Sci. Nutr. 35: 175-190, 1995.
32. Roncucci, L., D. Stamp, A. Medline, J. B. Cullen, and W. R. Bruce. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum. Pathol. 22: 287-294, 1991.
33. Rubin, N. H., P. Singh, G. Alinder, G. H. Greeley, Jr., P. L. Rayford, W. J. Rietveld, and J. C. Thompson. Circadian rhythms in gastrin receptors in the rat fundic stomach. Dig. Dis. Sci. 33: 931-937, 1988.
34. Seitz, J. F., M. Giovannini, J. Gouvernet, and A. P. Gauthier. Elevated serum gastrin levels in patients with colorectal neoplasia. J. Clin. Gastroenterol. 13: 541-545, 1991.
35. Seva, C., C. Dickinson, and T. Yamada. Growth-promoting effects of glycine-extended progastrin. Science 265: 410-412, 1994.
36. Simon, B., J. L. Merchant, R. Eissele, K. Kohler, and R. Arnold. Transient transcriptional activation of gastrin during sodium butyrate-induced differentiation of islet cells. Regul. Pept. 70: 143-148, 1997.
37. Singh, P., B. Dai, R. L. Given, X. Lu, and P. E. Holthuizen. Differential activation of IGF-II promoters P3 and P4 in CaCo2 cells during growth and differentiation. Gastroenterology 114: 1221-1229, 1998.
38. Singh, P., A. Owlia, R. Espeijo, and B. Dai. Novel gastrin receptors mediate mitogenic effects of gastrin processing intermediates of gastrin on Swiss 3T3 fibroblasts. J. Biol. Chem. 270: 8429-8438, 1995.
39. Singh, P., A. Owlia, A. Varro, B. Dai, S. Rajaraman, and T. Wood. Gastrin gene expression is required for the proliferation and tumorigenicity of human colon cancer cells. Cancer Res. 56: 4111-4115, 1996.
40. Singh, P., C. M. Townsend, Jr., J. C. Thompson, S. Narayan, and Y.-S. Guo. Hormones in colon cancer; past and prospective studies. Cancer J. 3: 28-33, 1990.
41. Singh, P., Z. Xu, B. Dai, S. Rajaraman, and B. Dhruva. Incomplete processing of progastrin expressed by colon cancer cells: role of non-carboxyamidated gastrin in proliferation. Am. J. Physiol. Gastrointest. Liver Physiol. 266: G459-G468, 1994.
42. Smith, A. J., H. S. Stern, M. Penner, K. Hay, A. Mitri, B. V. Bapat, and S. Gallinger. Somatic APC and K-ras condon 12 mutations in aberrant crypt foci from human colons. Cancer Res. 54: 5527-5530, 1994.
43. Smith, J. P., J. G. Wood, and T. E. Solomon. Elevated gastrin levels in patients with colon cancer or adenomatous polyps. Dig. Dis. Sci. 34: 171-174, 1989.
44. Sobhani, I., T. Lehy, P. Laurent-Puig, G. Cadiot, P. Ruszniewski, and M. Mignon. Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. Gastroenterology 105: 22-30, 1993.
45. Takayama, T., S. Katsuki, Y. Takahashi, M. Ohi, S. Nojiri, S. Sakamaki, J. Kato, K. Kogawa, and H. Miyake. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med. 339: 1277-1284, 1998.
46. Thorburn, C. M., G. D. Friedman, C. J. Dickinson, J. H. Vogelman, N. Orentreich, and J. Parsonnet. Gastrin and colorectal cancer: a prospective study. Gastroenterology 115: 275-280, 1998.
47. Townsend, C. M., Jr., P. Singh, and J. C. Thompson. Gastrointestinal hormones and gastrointestinal and pancreatic carcinomas. Gastroenterology 91: 1002-1006, 1986.
48. M. Velasco, T. Wang, R. Given, M. Wargovich, and P. Singh. Non-amidated gastrins, but not amidated gastrins function as co-carcinogens in an azoxymethane (AOM) induced colon cancer model (Abstract). Proc. Dig. Dis. Week (Orlando, FL), 1999, p. 640.
49. Wang, T. C., T. J. Koh, A. Varro, R. Cahill, C. A. Dangler, J. A. Fox, and G. J. Dockray. Processing and proliferative effects of human progastrin in transgenic mice. J. Clin. Invest. 98: 1918-1929, 1996.
50. Wank, S. A. G-protein-coupled receptors in gastrointestinal physiology. I. CCK receptor: an exemplary family. Am. J. Physiol. Gastrointest. Liver Physiol. 274: G607-G613, 1998.
51. Wargovich, M. J., C. D. Chen, C. Harris, E. Yang, and M. Velasco. Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int. J. Cancer 60: 515-519, 1995.
52. Zaidi, N. H., T. P. Pretlow, M. A. O'Riordan, L. L. Dumenco, E. Allay, and S. L. Gerson. Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. Carcinogenesis 16: 451-456, 1995.